Literature DB >> 1678892

Cellular immunity in schizophrenic patients before and during neuroleptic treatment.

N Müller1, M Ackenheil, E Hofschuster, W Mempel, R Eckstein.   

Abstract

A possible connection between immunological alterations and schizophrenia has been discussed for many years. We studied 55 schizophrenic patients in an acute stage of illness before they began neuroleptic treatment. 35 patients who showed clinical improvement on neuroleptics, and 51 healthy controls. Our interest was focused on parameters of cellular immunity. We found an increased lymphocyte response to stimulation with pokeweed mitogen (PWM) and phytohemagglutinin (PHA) in patients before neuroleptic therapy and also an increased response to stimulation with PWM and PHA during treatment compared to controls. Stimulation with antigens generally showed a lower lymphocyte response in patients than in controls, but the difference was only significant after stimulation with tuberculin before neuroleptic treatment and after stimulation with varidase, diphteria-toxoid, tuberculin, vaccinia, and rubella during neuroleptic treatment. The number of CD3+ and CD4+ cells, but not the number of CD8+ cells, was increased before and during treatment in comparison to controls. Suppressor-cell activity was reduced in three different suppressor cell assays before and during neuroleptic medication compared to controls. We therefore conclude that alterations of the immunological system which are, as has been demonstrated, not due to treatment with neuroleptics might play a role in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678892     DOI: 10.1016/0165-1781(91)90072-w

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  20 in total

Review 1.  [Immunology in schizophrenic disorders].

Authors:  N Müller; M J Schwarz
Journal:  Nervenarzt       Date:  2007-03       Impact factor: 1.214

2.  Immune System and Schizophrenia.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Curr Immunol Rev       Date:  2010-08

Review 3.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

4.  Abnormal levels of vascular endothelial biomarkers in schizophrenia.

Authors:  Tanya T Nguyen; Sheena I Dev; Guanqing Chen; Sharon C Liou; Averria Sirkin Martin; Michael R Irwin; Judith E Carroll; Xin Tu; Dilip V Jeste; Lisa T Eyler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-09-23       Impact factor: 5.270

5.  Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia.

Authors:  N Müller; M Empl; M Riedel; M Schwarz; M Ackenheil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

6.  Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients.

Authors:  I Wilke; V Arolt; M Rothermundt; C Weitzsch; M Hornberg; H Kirchner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 7.  Viruses, schizophrenia, and bipolar disorder.

Authors:  R H Yolken; E F Torrey
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

8.  Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects.

Authors:  Brian J Miller; Bintou Gassama; Dale Sebastian; Peter Buckley; Andrew Mellor
Journal:  Biol Psychiatry       Date:  2012-10-11       Impact factor: 13.382

Review 9.  A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders.

Authors:  Norbert Müller; Markus J Schwarz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06       Impact factor: 5.270

Review 10.  Comorbidity implications in brain disease: neuronal substrates of symptom profiles.

Authors:  Tomas Palomo; Richard J Beninger; Richard M Kostrzewa; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.